{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:46:15Z","timestamp":1785887175199,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-06043-w","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:45:47Z","timestamp":1780109147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the benefits and safety of combining nebivolol and valsartan for managing hypertension: a systematic review"],"prefix":"10.1186","volume":"26","author":[{"given":"Mohamed","family":"Khalid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojoud M.","family":"Majzoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen M.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatoon","family":"Makki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar M.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannan O.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashir A.","family":"Yousef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"6043_CR1","unstructured":"Iqbal AM, Jamal SF. Essential Hypertension. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539859\/.\u00a0Updated 2023 Jul 20."},{"issue":"3","key":"6043_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","volume":"94","author":"Y Xie","year":"2018","unstructured":"Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;94(3):567\u201381. https:\/\/doi.org\/10.1016\/j.kint.2018.04.011.","journal-title":"Kidney Int"},{"key":"6043_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.phrs.2017.11.003","volume":"129","author":"SE Kjeldsen","year":"2018","unstructured":"Kjeldsen SE. Hypertension and cardiovascular risk: General aspects. Pharmacol Res. 2018;129:95\u20139. https:\/\/doi.org\/10.1016\/j.phrs.2017.11.003.","journal-title":"Pharmacol Res"},{"issue":"12","key":"6043_CR4","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071. https:\/\/doi.org\/10.1097\/HJH.0000000000003480.","journal-title":"J Hypertens"},{"issue":"9","key":"6043_CR5","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/hr.2012.100","volume":"35","author":"M Morgado","year":"2012","unstructured":"Morgado M, Rolo S. Factors influencing medication adherence and hypertension management revisited: recent insights from cancer survivors. Hypertens Res. 2012;35(9):894\u20136. https:\/\/doi.org\/10.1038\/hr.2012.100.","journal-title":"Hypertens Res"},{"issue":"1","key":"6043_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.15420\/cfr.2017:5:1","volume":"3","author":"F Iellamo","year":"2017","unstructured":"Iellamo F, Werdan K, Narkiewicz K, Rosano G, Volterrani M. Practical Applications for Single Pill Combinations in the Cardiovascular Continuum. Card Fail Rev. 2017;3(1):40\u20135. https:\/\/doi.org\/10.15420\/cfr.2017:5:1.","journal-title":"Card Fail Rev"},{"issue":"5","key":"6043_CR7","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41440-024-01622-w","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Okura A, Hoshide S, Mogi M. The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res. 2024;47(5):1099\u2013102. https:\/\/doi.org\/10.1038\/s41440-024-01622-w.","journal-title":"Hypertens Res"},{"issue":"16","key":"6043_CR8","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacc.2009.05.066","volume":"54","author":"T M\u00fcnzel","year":"2009","unstructured":"M\u00fcnzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54(16):1491\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2009.05.066.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"6043_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2174\/157339910791658844","volume":"6","author":"AM Carella","year":"2010","unstructured":"Carella AM, Antonucci G, Conte M, Di Pumpo M, Giancola A, Antonucci E. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review. Curr Diabetes Rev. 2010;6(4):215\u201321. https:\/\/doi.org\/10.2174\/157339910791658844.","journal-title":"Curr Diabetes Rev"},{"key":"6043_CR10","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547944\/. Cited 2025 Dec 27."},{"issue":"4","key":"6043_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/00004872-200304000-00013","volume":"21","author":"CM Lawes","year":"2003","unstructured":"Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21(4):707\u201316. https:\/\/doi.org\/10.1097\/00004872-200304000-00013.","journal-title":"J Hypertens"},{"key":"6043_CR12","doi-asserted-by":"publisher","first-page":"18014","DOI":"10.1038\/nrdp.2018.14","volume":"4","author":"S Oparil","year":"2018","unstructured":"Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, C\u00edfkov\u00e1 R, Dominiczak AF, et al. Hypertens Nat Rev Dis Primers. 2018;4:18014. https:\/\/doi.org\/10.1038\/nrdp.2018.14.","journal-title":"Hypertens Nat Rev Dis Primers"},{"issue":"10","key":"6043_CR13","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/ajh\/hpac077","volume":"35","author":"S Navaneethabalakrishnan","year":"2022","unstructured":"Navaneethabalakrishnan S, Smith HL, Arenaz CM, Goodlett BL, McDermott JG, Mitchell BM. Update on Immune Mechanisms in Hypertension. Am J Hypertens. 2022;35(10):842\u201351. https:\/\/doi.org\/10.1093\/ajh\/hpac077.","journal-title":"Am J Hypertens"},{"issue":"1","key":"6043_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000320387","volume":"34","author":"I Drenjan\u010devi\u0107-Peri\u0107","year":"2011","unstructured":"Drenjan\u010devi\u0107-Peri\u0107 I, Jelakovi\u0107 B, Lombard JH, Kunert MP, Kibel A, Gros M. High-salt diet and hypertension: focus on the renin-angiotensin system. Kidney Blood Press Res. 2011;34(1):1\u201311. https:\/\/doi.org\/10.1159\/000320387.","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"6043_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/HYPERTENSIONAHA.110.163519","volume":"57","author":"LG Navar","year":"2011","unstructured":"Navar LG, Kobori H, Prieto MC, Gonzalez-Villalobos RA. Intratubular renin-angiotensin system in hypertension. Hypertension. 2011;57(3):355\u201362. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.163519.","journal-title":"Hypertension"},{"key":"6043_CR16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"1","key":"6043_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"6043_CR18","unstructured":"WebPlotDigitizer. 2025. Available from: https:\/\/automeris.io\/posts\/version_5\/. Cited 2025 June 26."},{"key":"6043_CR19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"6043_CR20","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"issue":"1","key":"6043_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res Synth Methods"},{"issue":"12","key":"6043_CR22","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.jash.2014.09.017","volume":"8","author":"JM Neutel","year":"2014","unstructured":"Neutel JM, Giles TD, Punzi H, Weiss RJ, Li H, Finck A. Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study. J Am Soc Hypertens. 2014;8(12):915\u201320. https:\/\/doi.org\/10.1016\/j.jash.2014.09.017.","journal-title":"J Am Soc Hypertens"},{"issue":"7","key":"6043_CR23","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jash.2015.03.009","volume":"9","author":"JL Izzo Jr","year":"2015","unstructured":"Izzo JL Jr, Khan SU, Saleem O, Osmond PJ. Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combination. J Am Soc Hypertens. 2015;9(7):526\u201335. https:\/\/doi.org\/10.1016\/j.jash.2015.03.009.","journal-title":"J Am Soc Hypertens"},{"issue":"4","key":"6043_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40292-018-0286-8","volume":"25","author":"SM Farag","year":"2018","unstructured":"Farag SM, Rabea HM, Mahmoud HB. Effect of Amlodipine\/Valsartan Versus Nebivolol\/Valsartan Fixed Dose Combinations on Peripheral and Central Blood Pressure. High Blood Press Cardiovasc Prev. 2018;25(4):407\u201313. https:\/\/doi.org\/10.1007\/s40292-018-0286-8.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"9932","key":"6043_CR25","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/S0140-6736(14)60614-0","volume":"383","author":"TD Giles","year":"2014","unstructured":"Giles TD, Weber MA, Basile J, Gradman AH, Bharucha DB, Chen W, et al. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet. 2014;383(9932):1889\u201398. https:\/\/doi.org\/10.1016\/S0140-6736(14)60614-0.","journal-title":"Lancet"},{"issue":"11","key":"6043_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jash.2015.08.003","volume":"9","author":"TD Giles","year":"2015","unstructured":"Giles TD, Bakris G, Oparil S, Weber MA, Li H, Mallick M, et al. Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. J Am Soc Hypertens. 2015;9(11):845\u201354. https:\/\/doi.org\/10.1016\/j.jash.2015.08.003.","journal-title":"J Am Soc Hypertens"},{"issue":"6","key":"6043_CR27","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/jch.12965","volume":"19","author":"CW Mende","year":"2017","unstructured":"Mende CW, Giles TD, Bharucha DB, Ferguson WG, Mallick M, Patel MD. Efficacy of nebivolol-valsartan single-pill combination in obese and nonobese patients with hypertension. J Clin Hypertens (Greenwich). 2017;19(6):632\u20139. https:\/\/doi.org\/10.1111\/jch.12965.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"9762","key":"6043_CR28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S0140-6736(10)62003-X","volume":"377","author":"MJ Brown","year":"2011","unstructured":"Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet. 2011;377(9762):312\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(10)62003-X.","journal-title":"Lancet"},{"issue":"1","key":"6043_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jash.2010.02.005","volume":"4","author":"AH Gradman","year":"2010","unstructured":"Gradman AH, Basile JN, Carter BL, Bakris GL, American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(1):42\u201350. https:\/\/doi.org\/10.1016\/j.jash.2010.02.005.","journal-title":"J Am Soc Hypertens"},{"issue":"7","key":"6043_CR30","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.amjhyper.2007.02.017","volume":"20","author":"MR Weir","year":"2007","unstructured":"Weir MR, Levy D, Crikelair N, Rocha R, Meng X, Glazer R. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens. 2007;20(7):807\u201315. https:\/\/doi.org\/10.1016\/j.amjhyper.2007.02.017.","journal-title":"Am J Hypertens"},{"issue":"Suppl 1","key":"6043_CR31","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1038\/sj.jhh.1001886","volume":"19","author":"F Zannad","year":"2005","unstructured":"Zannad F. Managing hypertension: a question of STRATHE. J Hum Hypertens. 2005;19(Suppl 1):S3\u20137. https:\/\/doi.org\/10.1038\/sj.jhh.1001886.","journal-title":"J Hum Hypertens"},{"issue":"3","key":"6043_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1023\/a:1026180325278","volume":"17","author":"I Czuriga","year":"2003","unstructured":"Czuriga I, Riecansky I, Bodnar J, Fulop T, Kruzsicz V, Kristof E, et al. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther. 2003;17(3):257\u201363. https:\/\/doi.org\/10.1023\/a:1026180325278.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"6043_CR33","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.semnephrol.2014.04.004","volume":"34","author":"BM Egan","year":"2014","unstructured":"Egan BM, Li J. Role of aldosterone blockade in resistant hypertension. Semin Nephrol. 2014;34(3):273\u201384. https:\/\/doi.org\/10.1016\/j.semnephrol.2014.04.004.","journal-title":"Semin Nephrol"},{"issue":"7","key":"6043_CR34","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1097\/HJH.0000000000000221","volume":"32","author":"G Parati","year":"2014","unstructured":"Parati G, Stergiou G, O\u2019Brien E, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7):1359\u201366. https:\/\/doi.org\/10.1097\/HJH.0000000000000221.","journal-title":"J Hypertens"},{"issue":"38","key":"6043_CR35","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178.","journal-title":"Eur Heart J"},{"issue":"5","key":"6043_CR36","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cjca.2020.02.086","volume":"36","author":"DM Rabi","year":"2020","unstructured":"Rabi DM, McBrien KA, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski SM, et al. Hypertension Canada\u2019s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Can J Cardiol. 2020;36(5):596\u2013624. https:\/\/doi.org\/10.1016\/j.cjca.2020.02.086.","journal-title":"Can J Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06043-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06043-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06043-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:04:17Z","timestamp":1785884657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-06043-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6043"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06043-w","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"660"}}